 CymaBay Therapeutics NASDAQ:CBAYs stock had its buy rating reaffirmed by equities research analysts at B. Riley in a research note issued to investors on Tuesday, TipRanks reports. They currently have a 9.00 price target on the biopharmaceutical companys stock. B. Rileys price objective indicates a potential upside of 84.43 from the companys previous close. CBAY ... 